An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
covid-19
Rhea-AI Summary
Therapeutic Solutions International has received a Notice of Allowance from the United States Patent and Trademark Office for its patent on QuadraMune®, a nutraceutical aimed at enhancing the immune system by inhibiting the indolamine 2,3 deoxygenase (IDO) pathway. This is a pioneering patent for a nutraceutical supplement in this area. The company aims to tap into the $15.2 billion checkpoint inhibitor market. Several ingredients in QuadraMune have shown potential anti-COVID effects, validated by independent universities after patent filing.
Positive
First patent issued for a nutraceutical targeting the IDO pathway.
$15.2 billion market opportunity in checkpoint inhibitors.
Potential anti-COVID properties of ingredients validated by independent studies.
Negative
None.
QuadraMune® Commercially Available “Checkpoint Inhibitor Nutraceutical” Shown to Target Immune Suppressive Indolamine 2,3 Deoxygenase Pathway
OCEANSIDE, Calif.--(BUSINESS WIRE)--
Therapeutic Solutions International announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase.”
To the knowledge of the Company, this is the first issuance of a patent on a nutraceutical supplement for stimulating the immune system by blocking immune suppressive activities used by cancer and viruses in the IDO pathway. The supplement, termed “QuadraMune®” is commercially available on the Company website and through Amazon.
Numerous drugs such as Optivo®, Yervoy®, and Keytruda®, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms. This class of drugs, called “checkpoint inhibitors” represent a 15.2 billion dollar a year market1.
“The indolamine 2,3 deoxygenase (IDO) pathway is believed to be one of the major immunological checkpoints based on the fact that small molecule blockade of this pathway results in immune mediated destruction of tumors in animals,” stated Dr. Thomas Ichim, Board Member and Co-Inventor of the patent. “Unfortunately, prior approaches to suppress this pathway relied on toxic compounds which did not perform well in clinical trials, in part due to inability to administer sufficient doses without evoking toxicity. We are excited by the possibility that QuadraMune®, a nutraceutical composition that is commercially available may act as a potent immune booster targeting the IDO pathway without drawbacks of other approaches.”
In 20132 and subsequently in 20183, Dr. Ichim and colleagues published regression of breast cancer by inhibiting the IDO pathway using an RNA interference approach. The current data and patent granted are representation of years of basic scientific investigation on the relationship between IDO and the immune system.
“As a physician that sees firsthand the devastation caused by cancer and viruses, I am extremely excited about our ability to modulate critical immunological pathways using naturally occurring ingredients such as pterostilbene, thymoquinone, epigallocatechin gallate and sulforaphane,” said Dr. James Veltmeyer, Chief Medical Officer of the Company and Co-Inventor of the patent. “What is particularly important is that after filing of our patents, numerous independent universities have validated the anti-COVID activity of the individual ingredients. These studies are summarized in our previous press release4.”
“The acceptance of our data by the United States Patent Office in granting of the current patent is a major accomplishment for the Company,” said Timothy Dixon, President and CEO, and Co-Inventor of the patent. “The Company has numerous patent applications filed covering multiple nutraceuticals and uses including; a) published patent application #16/866430 entitled ‘Nutraceuticals for the Prevention, Inhibition, and Treatment of SARS-Cov-2 and Associated COVID-19’, b) #16/898472 entitled ‘Nutraceuticals for Reducing Myeloid Suppressor Cells’ and c) #16/907335 entitled ‘Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity’.”
QuadraMune® is a nutraceutical supplement designed to enhance the immune system by blocking the indolamine 2,3 deoxygenase (IDO) pathway, which is a significant immunological checkpoint.
What recent patent did Therapeutic Solutions International receive?
The company received a Notice of Allowance for a patent on nutraceuticals designed to suppress the IDO pathway, marking a significant milestone.
How does the patent impact the market for Therapeutic Solutions International (TSOI)?
The patent opens opportunities in a $15.2 billion market dominated by checkpoint inhibitors, positioning TSOI advantageously in the immune modulation sector.
What are the key ingredients in QuadraMune®?
QuadraMune® includes ingredients like pterostilbene, thymoquinone, epigallocatechin gallate, and sulforaphane, which are believed to enhance immune response.
Has the efficacy of QuadraMune® been scientifically validated?
Yes, independent universities have validated the anti-COVID activity of QuadraMune®'s ingredients following the patent filing.
